Dr Milad Ibrahim speaks to ecancer about EGFR, a promising therapeutic target in NF1 mutant melanoma.

This study explores NF1 mutant melanoma, an aggressive subtype with limited treatment options.

Researchers classify melanoma into three subtypes and analyse patient-derived cell lines.

They find that EGFR is upregulated in NF1 mutant melanoma, and inhibiting EGFR causes cell death.

Existing drugs like Cetuximab show promise in reducing tumour growth in preclinical models, suggesting potential for clinical use and the need for further research on EGFR targeting in other cancers.